FDA Deputy Commissioner Stephen Spielberg, MD, PhD, spoke on advancing the regulatory process.
Yaffa Rubinstein, PhD, of NIH poses a question.
Duke University Vice Chancellor Robert Califf, MD, outlines criteria for avoiding a crisis in clinical trials.
There are breakout sessions in addition to plenary sessions.
Preston Campbell III, MD, Executive Vice President for Medical Affairs of the Cystic Fibrosis Foundation, walks the audience through the process that led to a new drug approved this year that many consider a medical breakthrough.